Recently published research from Global Markets Direct, "Clavis Pharma ASA - Product Pipeline Review - 2012", is now available at Fast Market Research
Boston, MA -- (SBWIRE) -- 12/19/2012 -- Global Market Direct's pharmaceuticals report, "Clavis Pharma ASA - Product Pipeline Review - 2012" provides data on the Clavis Pharma ASA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Clavis Pharma ASA's corporate website, SEC filings, investor presentations and featured press releases, both from Clavis Pharma ASA and industry-specific third party sources, put together by Global Markets Direct's team.
- Clavis Pharma ASA - Brief Clavis Pharma ASA overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Clavis Pharma ASA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Clavis Pharma ASA with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Clavis Pharma ASA's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
View Full Report Details and Table of Contents
Reasons to Get this Report
- Evaluate Clavis Pharma ASA's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Clavis Pharma ASA in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Clavis Pharma ASA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Clavis Pharma ASA.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Clavis Pharma ASA and identify potential opportunities in those areas.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Clavis Pharma ASA - Product Pipeline Review - Q1 2011
- Bionor Pharma ASA - Product Pipeline Review - 2012
- Clavis Pharma ASA (CLAVIS) - Financial and Strategic SWOT Analysis Review
- Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2012
- Viral Infections - Pipeline Review, H2 2012
- Dainippon Sumitomo Pharma Co., Ltd. - Product Pipeline Review - 2012
- Shionogi & Co., Ltd. - Product Pipeline Review - 2012
- LEO Pharma A/S - Product Pipeline Review - 2012
- Astellas Pharma Inc. - Product Pipeline Review - 2012
- Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2012